Molecular basis for sunitinib efficacy and future clinical development

By S. Faivre, G. Demetri, W. Sargent, E. Raymond. Nature reviews. Drug discovery, 2007

734 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Therapeutic peptides: current applications and future directions (2022, background): “Efficacy and pharmacokinetics of subcutaneous exendin (9-39) in patients with post-bariatric hypoglycaemia.”
Endothelial adherens junctions control tight junctions by VE-cadherin-mediated upregulation of claudin-5 (2008, background): “S4a, b ) or with sunitinib malate (SU11248), a chemical inhibiting VEGF-receptor 2 tyrosine kinase activit”
Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. (2009, background): “This difference could be due to the differential specificity of inhibition by the two drugs: sunitinib potently blocks not only VEGFR2 and the PDGFRs but also lymphatic vessel-related VEGFR3 (Faivre et al., 2007; Roskoski, 2007).”
Paul Ehrlich's magic bullet concept: 100 years of progress (2008, result): “, and results indicate that multi-kinase inhibitors are suitable targeted drugs that, surprisingly, are in accord with Ehrlich's concep”
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. (2011, neutral): “Anorexia 18 (22) 16 (19) 2 (2) 17 (21) 16 (20) 1 (1)”